Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity

Clinical trial NCT00358293 · COMPLETED

Trial details

NCT number: NCT00358293
Sponsor: Teva GTC
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Muscle Spasticity

Start date: 2006-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.